Oncoveda Cancer Research Center
Oncoveda is a cancer research center established in May 2010, focusing on early detection, monitoring, and treatment of gynecologic and urologic cancers. It aims to understand tumor progression, identify cancer biomarkers and drug targets, and translate discoveries into clinical tests and therapeutics. Part of Medical Diagnostic Laboratories LLC and the Genesis Biotechnology Group, Oncoveda collaborates on clinical validation studies, research projects, and drug discovery to advance cancer diagnostics and therapeutics.
Industries
Nr. of Employees
small (1-50)
Oncoveda Cancer Research Center
Products
Urine-based biomarker diagnostic assay for bladder cancer (in development)
A urine-based immunoassay under clinical evaluation to detect a protein biomarker found in bladder cancer patients for non-invasive diagnosis.
Small-molecule discovery programs (preclinical)
Research programs focused on identifying and developing small-molecule inhibitors against validated oncology targets including epigenetic enzymes, Wnt and NF-κB pathway components, and immune-modulatory targets.
Urine-based biomarker diagnostic assay for bladder cancer (in development)
A urine-based immunoassay under clinical evaluation to detect a protein biomarker found in bladder cancer patients for non-invasive diagnosis.
Small-molecule discovery programs (preclinical)
Research programs focused on identifying and developing small-molecule inhibitors against validated oncology targets including epigenetic enzymes, Wnt and NF-κB pathway components, and immune-modulatory targets.
Services
End-to-end development of biomarker-based diagnostic assays including discovery, analytical assay development, prospective clinical validation, and transfer to clinical diagnostic labs or commercialization partners.
Collaborative programs to evaluate validated targets, develop HTS assays, and screen large compound collections to identify candidate small molecules for preclinical development.
End-to-end development of biomarker-based diagnostic assays including discovery, analytical assay development, prospective clinical validation, and transfer to clinical diagnostic labs or commercialization partners.
Collaborative programs to evaluate validated targets, develop HTS assays, and screen large compound collections to identify candidate small molecules for preclinical development.
Expertise Areas
- Biomarker discovery and clinical validation
- Diagnostic assay development and analytical validation
- Clinical study coordination for diagnostic trials
- High-throughput screening and small-molecule discovery
Key Technologies
- Enzyme-linked immunosorbent assay (ELISA)
- Real-time PCR / quantitative PCR
- Methylation-specific PCR
- Cell culture and trans-well migration assays
News & Updates
Updated Website!
The Oncoveda website has been fully updated, showcasing current programs and scientific members.
Projects for Lab Rotations/Internships
Information about available lab rotation and internship projects at Oncoveda.
Article Accepted into Tumor Biology
Publication of research on PME-1's role in endometrial cancer tumor progression.
Research on the role of cancerous inhibitor of PP2A in prostate cancer.
Publication of research articles on cancer biomarkers and mechanisms
Multiple peer-reviewed publications in cancer research journals.
Updated Website!
The Oncoveda website has been fully updated, showcasing current programs and scientific members.
Projects for Lab Rotations/Internships
Information about available lab rotation and internship projects at Oncoveda.
Article Accepted into Tumor Biology
Publication of research on PME-1's role in endometrial cancer tumor progression.
Research on the role of cancerous inhibitor of PP2A in prostate cancer.
Publication of research articles on cancer biomarkers and mechanisms
Multiple peer-reviewed publications in cancer research journals.